Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study.

Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study.

<h4>Background</h4>Ustekinumab, is a new therapy for patients with IBD, especially for patients suffering from Crohn's disease (CD) who did not respond to anti-TNF treatment. To shed light on the longitudinal effect of ustekinumab on the immune system, we investigated the effect on...

Full description

Bibliographic Details
Main Authors: Filip Rob, Dagmar Schierova, Zuzana Stehlikova, Jakub Kreisinger, Radka Roubalova, Stepan Coufal, Martin Mihula, Zuzana Jackova, Miloslav Kverka, Tomas Thon, Klara Kostovcikova, Lukas Bajer, Pavel Drastich, Jana Tresnak Hercogova, Michaela Novakova, Martin Kolar, Martin Vasatko, Milan Lukas, Helena Tlaskalova-Hogenova, Zuzana Jiraskova Zakostelska
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0277576

Internet

https://doi.org/10.1371/journal.pone.0277576

Similar Items